These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

253 related articles for article (PubMed ID: 37939766)

  • 21. Functionalized biomimetic nanoparticles combining programmed death-1/programmed death-ligand 1 blockade with photothermal ablation for enhanced colorectal cancer immunotherapy.
    Xiao Y; Zhu T; Zeng Q; Tan Q; Jiang G; Huang X
    Acta Biomater; 2023 Feb; 157():451-466. PubMed ID: 36442821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Focus on immune checkpoint PD-1/PD-L1 pathway: New advances of polyphenol phytochemicals in tumor immunotherapy.
    Liu K; Sun Q; Liu Q; Li H; Zhang W; Sun C
    Biomed Pharmacother; 2022 Oct; 154():113618. PubMed ID: 36055113
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 (B7-H1) Competes with the RNA Exosome to Regulate the DNA Damage Response and Can Be Targeted to Sensitize to Radiation or Chemotherapy.
    Tu X; Qin B; Zhang Y; Zhang C; Kahila M; Nowsheen S; Yin P; Yuan J; Pei H; Li H; Yu J; Song Z; Zhou Q; Zhao F; Liu J; Zhang C; Dong H; Mutter RW; Lou Z
    Mol Cell; 2019 Jun; 74(6):1215-1226.e4. PubMed ID: 31053471
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Checkpoint Blockade Mediated by a Small-Molecule Nanoinhibitor Targeting the PD-1/PD-L1 Pathway Synergizes with Photodynamic Therapy to Elicit Antitumor Immunity and Antimetastatic Effects on Breast Cancer.
    Zhang R; Zhu Z; Lv H; Li F; Sun S; Li J; Lee CS
    Small; 2019 Dec; 15(49):e1903881. PubMed ID: 31702880
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Coadministration of iRGD peptide with ROS-sensitive nanoparticles co-delivering siFGL1 and siPD-L1 enhanced tumor immunotherapy.
    Wan WJ; Huang G; Wang Y; Tang Y; Li H; Jia CH; Liu Y; You BG; Zhang XN
    Acta Biomater; 2021 Dec; 136():473-484. PubMed ID: 34571271
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DNA damage response and PD-1/PD-L1 pathway in ovarian cancer.
    Zhang T; Zheng S; Liu Y; Li X; Wu J; Sun Y; Liu G
    DNA Repair (Amst); 2021 Jun; 102():103112. PubMed ID: 33838550
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Regulation of post-translational modification of PD-L1 and advances in tumor immunotherapy.
    Feng C; Zhang L; Chang X; Qin D; Zhang T
    Front Immunol; 2023; 14():1230135. PubMed ID: 37554324
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naïve Vision of a Single Biomarker.
    Signorelli D; Giannatempo P; Grazia G; Aiello MM; Bertolini F; Mirabile A; Buti S; Vasile E; Scotti V; Pisapia P; Cona MS; Rolfo C; Malapelle U;
    Biomed Res Int; 2019; 2019():9056417. PubMed ID: 31179334
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Extrinsic and Intrinsic Roles of PD-L1 and Its Receptor PD-1: Implications for Immunotherapy Treatment.
    Hudson K; Cross N; Jordan-Mahy N; Leyland R
    Front Immunol; 2020; 11():568931. PubMed ID: 33193345
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Spatial and Temporal Changes in PD-L1 Expression in Cancer: The Role of Genetic Drivers, Tumor Microenvironment and Resistance to Therapy.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 32992658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Burgeoning Exploration of the Role of Natural Killer Cells in Anti-PD-1/PD-L1 Therapy.
    Bai R; Cui J
    Front Immunol; 2022; 13():886931. PubMed ID: 35634343
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.
    Ai L; Xu A; Xu J
    Adv Exp Med Biol; 2020; 1248():33-59. PubMed ID: 32185706
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade.
    Jiang Y; Zhao X; Fu J; Wang H
    Front Immunol; 2020; 11():339. PubMed ID: 32226426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recent advances in the clinical development of immune checkpoint blockade therapy.
    Ghahremanloo A; Soltani A; Modaresi SMS; Hashemy SI
    Cell Oncol (Dordr); 2019 Oct; 42(5):609-626. PubMed ID: 31201647
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.
    Gong C; Yu X; Zhang W; Han L; Wang R; Wang Y; Gao S; Yuan Y
    J Nanobiotechnology; 2021 Feb; 19(1):58. PubMed ID: 33632231
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Regulation of PD-L1 posttranslational modification and its application progress in tumor immunotherapy].
    Su Y; Wang Q; Ru Y; Dong J; Li X; Zhang Z
    Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2022 Nov; 38(11):1036-1043. PubMed ID: 36328434
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A phenolic based tumor-permeated nano-framework for immunogenic cell death induction combined with PD-L1 immune checkpoint blockade.
    Sun X; Zhang J; Xiu J; Zhao X; Yang C; Li D; Li K; Hu H; Qiao M; Chen D; Zhao X
    Biomater Sci; 2022 Jul; 10(14):3808-3822. PubMed ID: 35670432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Roles of tumor-associated macrophages in anti-PD-1/PD-L1 immunotherapy for solid cancers.
    Zhang H; Liu L; Liu J; Dang P; Hu S; Yuan W; Sun Z; Liu Y; Wang C
    Mol Cancer; 2023 Mar; 22(1):58. PubMed ID: 36941614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A preclinical study: correlation between PD-L1 PET imaging and the prediction of therapy efficacy of MC38 tumor with
    Qin S; Yu Y; Guan H; Yang Y; Sun F; Sun Y; Zhu J; Xing L; Yu J; Sun X
    Aging (Albany NY); 2021 Apr; 13(9):13006-13022. PubMed ID: 33910164
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9-genome editing promotes antitumor immunity and suppresses ovarian cancer progression.
    Yahata T; Mizoguchi M; Kimura A; Orimo T; Toujima S; Kuninaka Y; Nosaka M; Ishida Y; Sasaki I; Fukuda-Ohta Y; Hemmi H; Iwahashi N; Noguchi T; Kaisho T; Kondo T; Ino K
    Cancer Sci; 2019 Apr; 110(4):1279-1292. PubMed ID: 30702189
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.